

Fall Group Meeting Chicago Specials

SEPTEMBER 18-20, 2025

Prevention, Screening, and
Surveillance Committee

Prevention, Screening, & Surveillance Committee

Leadership

Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO

Time/Location

Thursday, September 18, 2025 2:00 p.m. - 4:00 p.m.

Room: Regency A (Ballroom Level, West Tower)

Agenda

Welcome and Opening Comments: Dr. Jason Zell &
 Dr. Banu Arun

Presentation: Targeting Metabolic Perturbation to Improve Cancer Risk and Outcomes - Neil M. Iyengar, MD, Associate Professor, Winship Cancer Institute at Emory University

Closed Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20. Closed: 5/20/24.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20. Closed 6/14/24.

Concepts in Development (not yet approved by Triage)

A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial of Finasteride to Prevent Recurrence in Patients with Low-Grade Intermediate-Risk NMIBC." Drs. S. Psutka and P. Hensley.

"Randomized Phase IIb Trial of Trifluridine/Tipiracil (FTD/TPI) and Irinotecan (IRI) For Molecular Residual Disease (MRD) Positive Colorectal Adenocarcinomas (CRC) Recurrent or Refractory to

Standard Curative Intent Multimodality Treatment." Drs. F. Dayyani and J. Zell.

"Randomized trial of Radiation with or without HER2 targeted therapy (trastuzumab) in DCIS patients identified as Residual Risk by DCISionRT testing". Dr. E. Connolly.

"Decision-T app-based intervention for smoking cessation." Dr. I. Tami-Maury.

Patient Advocate Update: Cheryl Jernigan

Annual NCORP Meeting Update: Banu Arun
 Katherine Crew

Group Discussion

Other Group Prevention Studies with SWOG Study Champions

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

Other Group Screening Studies with SWOG Study Champions or SWOG Accrual

CTSU/NRG-CC005, "FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)". Dr. L. Kachnic. Activated: 10/6/21.

CTSU/NRG-CC008, "A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]." Activated: 6/23/20

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 7/6/17. Closed to accrual: 12/20/24.

CTSU A212102, "Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

CTSU/EA2185, "Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers"/ Activated: 1/16/20. Temporarily Closed to Accrual as of 3/1/24.

Prevention, Screening, & Surveillance Committee

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>S1823</i>	<i>S1904</i>	<i>A211801</i>	<i>A212102</i>	<i>EA1151</i>	<i>EA2185</i>	<i>EA8184</i>	<i>NRGCC005</i>	<i>NRGCC008</i>
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	263	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	51	-	-	4	2	-
Banner MD Anderson Cancer Center	5	-	-	-	1	-	-	-	-
Banner University Medical Center - Tucson	14	-	-	-	56	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	12	-	-	8	-	-	-	-
Bay Area Tumor Institute NCORP	1	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	3	-	-	5
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	2	290	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	5	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	6	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	5	26	-	-	2	-	-	-	-
City of Hope Comprehensive Cancer Center	-	20	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	42	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	7	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	5	-	-	-	100	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	105	-	-	-	-
Gulf South Minority Underserved NCORP	13	-	-	5	-	-	-	-	2
Hawaii Minority Underserved NCORP	3	21	-	-	80	-	-	-	-
Heartland Cancer Research NCORP	15	11	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	4	133	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	178	15	-	-	-	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	5	-	-	-	10	-
Lahey Hospital and Medical Center	-	3	-	-	-	-	-	-	-
Loma Linda University Medical Center	8	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	4	-	-	-	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	-	-	4	-
Massachusetts Vets Epidemiology Research & Information Center	-	-	-	27	-	8	-	35	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	2	4	-	4	-	-
Memorial Hermann Texas Medical Center	-	-	-	-	8	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	11	-	-	-	463	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	12	-	-	-	-	-	-	-	-

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>S1823</i>	<i>S1904</i>	<i>A211801</i>	<i>A212102</i>	<i>EA1151</i>	<i>EA2185</i>	<i>EA8184</i>	<i>NRGCC005</i>	<i>NRGCC008</i>
Northwell Health NCORP	11	-	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	8	2	-	-	-	-	-	-	-
Oregon Health and Science University	17	-	-	-	-	3	3	13	3
Pacific Cancer Research Consortium NCORP	-	1	-	-	-	-	-	-	-
Regents of the University of Michigan	-	-	1	-	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-	-	-	-
Salem Hospital	3	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	2	-	-	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	5	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	2	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	1	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	4	-	-	91	-	-	-	-	-
UC San Diego Moores Cancer Center	24	-	-	-	-	1	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	30	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	33	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	389	3	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	6	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	26	-	-	5	2	-	-	13	-
University of Kentucky/Markey Cancer Center	-	-	-	-	9	-	-	-	-
University of Mississippi Medical Center	6	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	8	-	-	-	-	-	-	-	-
University of Rochester LAPS	20	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-	20	-	-	-	-	1
University of Utah - Huntsman Cancer Institute LAPS	-	21	-	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	-	619	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	7	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	16	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	8	-	-	-	-
Western States Cancer Research NCORP	5	-	-	-	73	-	-	-	-
ALLIANCE	96	106	-	-	-	-	-	-	-
CCTG	217	-	-	-	-	-	-	-	-
ECOG-ACRIN	76	43	-	-	-	-	-	-	-
NRG	55	85	-	-	-	-	-	-	-
Total	964	412	1	217	2,615	19	12	77	12

